ETF Home ETF List Shorted Stocks Home About

Portfolio Holdings Detail for ISIN IE00B3VWM098
Stock Name / FundiShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
IssuerBlackrock
Entity holding fund iShares VII Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300Q7FFITMZ2PFZ28
ETF TickerCUS1(GBX) LSE
ETF TickerCUSS(USD) LSE
ETF TickerSXRG(EUR) F
ETF TickerCSUSS.MI(EUR) CXE
ETF TickerCSUSSz(USD) CXE
ETF TickerCUSS.LS(USD) CXE
ETF TickerCSUSS(EUR) ETF Plus
ETF TickerCUS1.L(GBP) LSE
ETF TickerCUSS.L(GBP) LSE

Holdings detail for VRDN

Stock NameViridian Therapeutics Inc
TickerVRDN(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS92790C1045
LEI549300C775BNYF550E70

Show aggregate VRDN holdings

News associated with VRDN

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives $37.78 Consensus Price Target from Brokerages
Viridian Therapeutics, Inc. (NASDAQ:VRDN – Get Free Report) has earned an average rating of “Moderate Buy” from the ten research firms that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average twelve-month […] - 2025-08-29 03:04:50
Jefferies Financial Group Begins Coverage on Viridian Therapeutics (NASDAQ:VRDN)
Jefferies Financial Group started coverage on shares of Viridian Therapeutics (NASDAQ:VRDN – Free Report) in a report published on Monday. The brokerage issued a buy rating and a $44.00 target price on the stock. A number of other equities research analysts have also recently commented on VRDN. Wells Fargo & Company decreased their target price […] - 2025-08-26 03:04:49
Deutsche Bank AG Reduces Stock Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN)
Deutsche Bank AG decreased its holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN – Free Report) by 1.5% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 396,808 shares of the company’s stock after selling 6,066 shares during the quarter. Deutsche Bank AG’s holdings in […] - 2025-08-17 05:14:56
TD Asset Management Inc Trims Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)
TD Asset Management Inc lessened its position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN – Free Report) by 36.3% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 32,600 shares of the company’s stock after selling 18,600 shares during the quarter. TD Asset Management Inc’s […] - 2025-08-05 04:34:53
Analysts See 19% Gains Ahead For FHLC
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-07-14 09:54:06
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Average Recommendation of “Moderate Buy” from Brokerages
Viridian Therapeutics, Inc. (NASDAQ:VRDN – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the ten brokerages that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 1 year price target among […] - 2025-07-07 05:11:43
Rhumbline Advisers Buys 4,621 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)
Rhumbline Advisers lifted its stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN – Free Report) by 4.6% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 104,559 shares of the company’s stock after acquiring an additional 4,621 shares during the quarter. Rhumbline Advisers’ […] - 2025-06-19 04:10:54
Squarepoint Ops LLC Lowers Stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN)
Squarepoint Ops LLC reduced its stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN – Free Report) by 23.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 33,251 shares of the company’s stock after selling 10,328 shares during the quarter. Squarepoint Ops LLC’s holdings in […] - 2025-06-04 05:06:50
Nuveen Asset Management LLC Has $13.06 Million Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)
Nuveen Asset Management LLC boosted its holdings in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN – Free Report) by 198.2% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 681,012 shares of the company’s stock after acquiring an additional 452,627 shares during the quarter. Nuveen Asset […] - 2025-05-27 06:05:03
Viridian Announces Positive Long-Term Data From Phase 3 Trial Of Veligrotug In Thyroid Eye Disease
(RTTNews) - Viridian Therapeutics Inc. (VRDN) announced positive long-term durability data from the THRIVE phase 3 clinical trial of veligrotug or "veli", an intravenously delivered anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, in patients with active thyroid eye - 2025-05-20 08:29:45
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Stock Position Increased by Barclays PLC
Barclays PLC lifted its position in Viridian Therapeutics, Inc. (NASDAQ:VRDN – Free Report) by 25.9% during the fourth quarter, Holdings Channel reports. The institutional investor owned 157,860 shares of the company’s stock after buying an additional 32,463 shares during the quarter. Barclays PLC’s holdings in Viridian Therapeutics were worth $3,027,000 at the end of the […] - 2025-04-30 05:50:47
Analysts Set Viridian Therapeutics, Inc. (NASDAQ:VRDN) PT at $35.70
Viridian Therapeutics, Inc. (NASDAQ:VRDN – Get Free Report) has received an average recommendation of “Moderate Buy” from the twelve brokerages that are presently covering the stock, MarketBeat reports. Three analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 1-year target price among analysts […] - 2025-04-28 03:08:56
Geode Capital Management LLC Purchases 165,669 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)
Geode Capital Management LLC increased its holdings in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN – Free Report) by 11.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,658,980 shares of the company’s stock after acquiring an additional 165,669 shares […] - 2025-04-17 04:52:50
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Holdings Lifted by Corebridge Financial Inc.
Corebridge Financial Inc. grew its holdings in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN – Free Report) by 8.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 36,336 shares of the company’s stock after buying an additional 2,878 shares during […] - 2025-04-07 04:32:49
Comparing Viridian Therapeutics (NASDAQ:VRDN) & ACI Global (OTCMKTS:ACGJ)
ACI Global (OTCMKTS:ACGJ – Get Free Report) and Viridian Therapeutics (NASDAQ:VRDN – Get Free Report) are both industrials companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, institutional ownership, earnings and risk. Profitability This table compares ACI Global and Viridian […] - 2025-04-03 03:08:55
Swiss National Bank Boosts Stock Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN)
Swiss National Bank grew its position in Viridian Therapeutics, Inc. (NASDAQ:VRDN – Free Report) by 4.2% during the 4th quarter, HoldingsChannel.com reports. The fund owned 112,600 shares of the company’s stock after buying an additional 4,500 shares during the quarter. Swiss National Bank’s holdings in Viridian Therapeutics were worth $2,159,000 at the end of the […] - 2025-03-28 05:52:52
Brokerages Set Viridian Therapeutics, Inc. (NASDAQ:VRDN) Target Price at $35.70
Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the twelve research firms that are presently covering the company, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The […] - 2025-02-26 04:23:00
R Squared Ltd Takes $26,000 Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)
R Squared Ltd acquired a new stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN – Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 1,340 shares of the company’s stock, valued at approximately $26,000. A number of other hedge funds have also […] - 2025-02-05 06:42:52

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc VRDN holdings

DateNumber of VRDN Shares HeldBase Market Value of VRDN SharesLocal Market Value of VRDN SharesChange in VRDN Shares HeldChange in VRDN Base ValueCurrent Price per VRDN Share HeldPrevious Price per VRDN Share Held
2025-12-11 (Thursday)40,789USD 1,328,498VRDN holding decreased by -1223USD 1,328,4980USD -1,223 USD 32.57 USD 32.6
2025-12-10 (Wednesday)40,789USD 1,329,721VRDN holding increased by 32631USD 1,329,7210USD 32,631 USD 32.6 USD 31.8
2025-12-09 (Tuesday)40,789USD 1,297,090VRDN holding decreased by -3263USD 1,297,0900USD -3,263 USD 31.8 USD 31.88
2025-12-08 (Monday)40,789USD 1,300,353VRDN holding decreased by -5711USD 1,300,3530USD -5,711 USD 31.88 USD 32.02
2025-12-05 (Friday)40,789USD 1,306,064VRDN holding decreased by -17947USD 1,306,0640USD -17,947 USD 32.02 USD 32.46
2025-12-04 (Thursday)40,789USD 1,324,011VRDN holding increased by 47315USD 1,324,0110USD 47,315 USD 32.46 USD 31.3
2025-12-03 (Wednesday)40,789VRDN holding decreased by -715USD 1,276,696VRDN holding increased by 13729USD 1,276,696-715USD 13,729 USD 31.3 USD 30.43
2025-12-02 (Tuesday)41,504VRDN holding increased by 286USD 1,262,967VRDN holding decreased by -33339USD 1,262,967286USD -33,339 USD 30.43 USD 31.45
2025-12-01 (Monday)41,218USD 1,296,306VRDN holding decreased by -21021USD 1,296,3060USD -21,021 USD 31.45 USD 31.96
2025-11-28 (Friday)41,218USD 1,317,327VRDN holding increased by 9892USD 1,317,3270USD 9,892 USD 31.96 USD 31.72
2025-11-27 (Thursday)41,218USD 1,307,435USD 1,307,4350USD 0 USD 31.72 USD 31.72
2025-11-26 (Wednesday)41,218USD 1,307,435VRDN holding increased by 12778USD 1,307,4350USD 12,778 USD 31.72 USD 31.41
2025-11-25 (Tuesday)41,218VRDN holding decreased by -429USD 1,294,657VRDN holding decreased by -39296USD 1,294,657-429USD -39,296 USD 31.41 USD 32.03
2025-11-24 (Monday)41,647VRDN holding decreased by -429USD 1,333,953VRDN holding increased by 57367USD 1,333,953-429USD 57,367 USD 32.03 USD 30.34
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of VRDN by Blackrock for IE00B3VWM098

Show aggregate share trades of VRDN

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-12-03SELL-715 31.300* 18.38 Profit of 13,144 on sale
2025-12-02BUY286 30.430* 18.33
2025-11-25SELL-429 31.410* 18.00 Profit of 7,723 on sale
2025-11-24SELL-429 32.030* 17.93 Profit of 7,694 on sale
2025-11-17SELL-1,584 29.000* 17.65 Profit of 27,961 on sale
2025-11-12SELL-144 28.940* 17.48 Profit of 2,518 on sale
2025-11-06SELL-144 27.500* 17.27 Profit of 2,487 on sale
2025-11-05SELL-1,440 24.420* 17.23 Profit of 24,816 on sale
2025-11-04SELL-288 22.550* 17.21 Profit of 4,955 on sale
2025-11-03SELL-28823.94022.700 22.824USD -6,573 17.17 Loss of -1,627 on sale
2025-10-28BUY43223.17023.300 23.287USD 10,060 17.04
2025-10-24SELL-14422.16022.540 22.502USD -3,240 16.98 Loss of -795 on sale
2025-10-15BUY86422.27022.290 22.288USD 19,257 16.74
2025-10-03BUY5,16621.65021.990 21.956USD 113,425 16.71
2025-10-02BUY12721.22021.920 21.850USD 2,775 16.69
2025-09-30BUY25421.58021.720 21.706USD 5,513 16.63
2025-09-11BUY50419.65020.340 20.271USD 10,217 16.54
2025-08-21SELL-25018.02018.289 18.262USD -4,566 16.53 Loss of -433 on sale
2025-07-31BUY75017.52017.925 17.884USD 13,413 16.51
2025-06-30SELL-50013.98014.710 14.637USD -7,318 16.53 Profit of 946 on sale
2025-06-25SELL-25014.70014.835 14.822USD -3,705 16.57 Profit of 437 on sale
2025-06-20SELL-50014.72015.245 15.192USD -7,596 16.61 Profit of 709 on sale
2025-05-23BUY25013.57013.655 13.646USD 3,412 16.94
2025-05-19SELL-25012.82013.205 13.166USD -3,292 17.06 Profit of 973 on sale
2025-05-15SELL-75012.62012.665 12.660USD -9,495 17.14 Profit of 3,356 on sale
2025-05-12SELL-25013.12013.380 13.354USD -3,339 17.25 Profit of 975 on sale
2025-05-09SELL-25012.39013.130 13.056USD -3,264 17.30 Profit of 1,060 on sale
2025-04-30SELL-25013.55013.755 13.735USD -3,434 17.59 Profit of 963 on sale
2025-04-24SELL-50013.56013.680 13.668USD -6,834 17.76 Profit of 2,044 on sale
2025-04-17SELL-25013.13013.150 13.148USD -3,287 17.99 Profit of 1,211 on sale
2025-04-15SELL-75012.80014.220 14.078USD -10,559 18.11 Profit of 3,020 on sale
2025-04-14SELL-75013.30013.459 13.443USD -10,082 18.16 Profit of 3,536 on sale
2025-04-09SELL-1,00011.79011.915 11.902USD -11,902 18.38 Profit of 6,474 on sale
2025-04-07SELL-1,75711.78012.160 12.122USD -21,298 18.54 Profit of 11,275 on sale
2025-04-04SELL-2,51011.99012.610 12.548USD -31,495 18.62 Profit of 15,231 on sale
2025-03-31BUY25113.48013.980 13.930USD 3,496 18.82
2025-03-19SELL-50215.43015.570 15.556USD -7,809 19.24 Profit of 1,849 on sale
2025-03-14SELL-1,50615.92016.350 16.307USD -24,558 19.39 Profit of 4,642 on sale
2025-03-13SELL-50415.81016.740 16.647USD -8,390 19.44 Profit of 1,408 on sale
2025-03-12SELL-8,56816.65017.000 16.965USD -145,356 19.48 Profit of 21,554 on sale
2025-03-07SELL-50415.94016.500 16.444USD -8,288 19.64 Profit of 1,613 on sale
2025-03-06SELL-75615.88016.150 16.123USD -12,189 19.70 Profit of 2,706 on sale
2025-03-03SELL-25214.41015.700 15.571USD -3,924 19.93 Profit of 1,099 on sale
2025-02-28BUY14,72715.53015.550 15.548USD 228,975 20.00
2025-02-26SELL-20915.53016.150 16.088USD -3,362 20.16 Profit of 851 on sale
2025-02-25SELL-62715.54016.110 16.053USD -10,065 20.24 Profit of 2,625 on sale
2025-02-18BUY1,04515.85016.690 16.606USD 17,353 20.62
2025-02-13BUY20917.02017.585 17.528USD 3,663 20.86
2025-02-12BUY20917.47017.755 17.726USD 3,705 20.93
2025-02-11BUY62717.86018.150 18.121USD 11,362 20.99
2025-02-06BUY1,88118.51019.440 19.347USD 36,392 21.18
2025-01-27BUY20918.91019.170 19.144USD 4,001 21.56
2024-12-30BUY1,04519.54019.610 19.603USD 20,485 21.86
2024-12-06BUY83619.72020.030 19.999USD 16,719 22.09
2024-12-05BUY20919.63020.240 20.179USD 4,217 22.17
2024-12-04BUY1,04019.96020.570 20.509USD 21,329 22.25
2024-11-29BUY1,04021.55022.220 22.153USD 23,039 22.42
2024-11-27BUY83221.87022.250 22.212USD 18,480 22.47
2024-11-26BUY20821.91022.230 22.198USD 4,617 22.49
2024-11-25BUY5,81921.03021.390 21.354USD 124,259 22.56
2024-11-21BUY95019.62020.410 20.331USD 19,314 22.84
2024-11-20BUY57019.79020.865 20.757USD 11,832 23.01
2024-11-18BUY2,28020.34020.380 20.376USD 46,457 23.35
2024-11-12BUY1,52022.43027.200 26.723USD 40,619 23.41
2024-11-08BUY95025.21025.280 25.273USD 24,009 23.28
2024-11-07BUY2,83524.71025.020 24.989USD 70,844 23.17
2024-11-06BUY37824.27024.673 24.633USD 9,311 23.08
2024-10-31BUY18921.57022.270 22.200USD 4,196 23.38
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of VRDN

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19171,3621,764230,61974.3%
2025-09-18197,3350240,13782.2%
2025-09-1779,3190135,03658.7%
2025-09-16133,5630173,39777.0%
2025-09-15248,5350306,44481.1%
2025-09-1260,1460149,32240.3%
2025-09-1170,0680108,83264.4%
2025-09-10215,1800270,70779.5%
2025-09-09100,6160683,73314.7%
2025-09-08114,4610228,00750.2%
2025-09-05109,0740259,64442.0%
2025-09-04118,5540377,67731.4%
2025-09-03192,175225585,00132.9%
2025-09-02117,0730436,53426.8%
2025-08-2958,1170293,24519.8%
2025-08-2869,6480199,43934.9%
2025-08-2773,786970160,95945.8%
2025-08-2677,3960222,95334.7%
2025-08-25124,0710326,79938.0%
2025-08-22107,4260683,70915.7%
2025-08-2176,878500260,64829.5%
2025-08-20154,457400269,64557.3%
2025-08-19248,61660709,46035.0%
2025-08-1897,9700264,13737.1%
2025-08-15175,4950428,60840.9%
2025-08-1485,7780128,71766.6%
2025-08-13157,9520514,64330.7%
2025-08-12202,6630420,09548.2%
2025-08-11158,9720212,49274.8%
2025-08-08139,1340304,97145.6%
2025-08-07234,6201,358301,23377.9%
2025-08-06373,8620553,06367.6%
2025-08-05181,2230338,20853.6%
2025-08-04106,962652165,30764.7%
2025-08-01181,2490208,16087.1%
2025-07-31233,188397275,39984.7%
2025-07-30348,5840462,30675.4%
2025-07-2992,2730134,09868.8%
2025-07-28160,4160213,27075.2%
2025-07-2596,0170221,68143.3%
2025-07-24117,6330194,31060.5%
2025-07-23165,3460266,72262.0%
2025-07-2261,343804105,26158.3%
2025-07-21131,2820269,18348.8%
2025-07-18114,9640161,36071.2%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Note: All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.

Copyright Market Footprint Ltd. Privacy Policy